In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat

被引:41
作者
Fischer, S [1 ]
Liu, MY [1 ]
MacLean, AA [1 ]
de Perrot, M [1 ]
Ho, M [1 ]
Cardella, JA [1 ]
Zhang, XM [1 ]
Bai, XH [1 ]
Suga, M [1 ]
Imai, Y [1 ]
Keshavjee, S [1 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Res Inst, Thorac Surg Res Lab,Toronto Lung Transplant Progr, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1089/10430340152480249
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We examined the effect of adenovirus-mediated transtracheal transfer of the human interleukin 10 (hIL-10) gene on lung ischemia-reperfusion (IR) injury, which is the insult due to hypothermic preservation plus graft reperfusion, and posttransplant lung function in Lewis rat lungs. Thirty rats were divided into 6 groups (n = 5). Groups 1 and 4 received 5 X 10(9) PFU of Ad5E1RSVhIL-10, groups 2 and 5 received 5 X 10(9) PFU of Ad5BGL2 ("empty" vector), and groups 3 and 6 received 3% sucrose (diluent). After 24 hr of in vivo transfection, lungs were stored at 4 degreesC (cold ischemic time, CIT) for 6 hr (groups 1-3) or 24 hr (groups 4-6) before transplantation. After 2 hr of reperfusion, lung function was assessed by oxygenation (FIo2, 1.0), airway pressure (AwP), and wet-to-dry (W/D) weight ratios. Rat tumor necrosis factor alpha (rTNF-alpha), interferon gamma (IFN-gamma), IL-10, and hIL-10 were measured in graft tissue and recipient plasma by ELISA and detected by immunohistochemistry (IHC). Partial pressure of oxygen (Pa-o2) levels in the hIL-10 group (6 hr of CIT) were higher than in empty vector and diluent groups (Pa-o2, 530 +/- 23 vs. 387 +/- 31 and 439 +/- 27 mmHg, respectively, p < 0.05). IL-10 rats after 24 hr of CIT showed higher Pa-o2 levels (260 +/- 29 mmHg) than empty vector (96 +/- 24 mmHg) or diluent (133 +/- 10 mmHg) lungs (p < 0.05). AwP and W/D ratios were reduced in hIL-10 lungs (p < 0.05) compared with the other groups. rTNF-<alpha> and INF-gamma were reduced in tissue and plasma in groups 1 and 4 (p < 0.05). rIL-10 was reduced in the tissue of hIL-10 lungs (p < 0.05). IHC showed equal distribution of cytokines in tissue and abundant transgene expression in large and small airway epithelium in hIL-10 lungs.
引用
收藏
页码:1513 / 1526
页数:14
相关论文
共 43 条
[1]   Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans [J].
Boehler, A ;
Chamberlain, D ;
Xing, Z ;
Slutsky, AS ;
Jordana, M ;
Gauldie, J ;
Liu, M ;
Keshavjee, S .
HUMAN GENE THERAPY, 1998, 9 (04) :541-551
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   EPSTEIN-BARR-VIRUS TRANSFORMATION INDUCES LYMPHOCYTES-B TO PRODUCE HUMAN INTERLEUKIN-10 [J].
BURDIN, N ;
PERONNE, C ;
BANCHEREAU, J ;
ROUSSET, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :295-304
[4]   Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression [J].
Cassivi, SD ;
Liu, MY ;
Boehler, A ;
Tanswell, AK ;
Slutsky, AS ;
Keshavjee, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (01) :1-7
[5]   Transtracheal gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation [J].
Cassivi, SD ;
Cardella, JA ;
Fischer, S ;
Liu, MY ;
Slutsky, AS ;
Keshavjee, S .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (12) :1181-1188
[6]   Gene therapy in lung transplantation: Feasibility of ex vivo adenovirus-mediated gene transfer to the graft [J].
Chapelier, A ;
Danel, C ;
Mazmanian, M ;
Bacha, EA ;
Sellak, H ;
Gilbert, MA ;
Herve, P ;
Lemarchand, P .
HUMAN GENE THERAPY, 1996, 7 (15) :1837-1845
[7]   Immune responses to adenovirus and adeno-associated virus in humans [J].
Chirmule, N ;
Propert, KJ ;
Magosin, SA ;
Qian, Y ;
Qian, R ;
Wilson, JM .
GENE THERAPY, 1999, 6 (09) :1574-1583
[8]  
Clarke CJP, 1998, EUR J IMMUNOL, V28, P1719, DOI 10.1002/(SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO
[9]  
2-Q
[10]  
Crocetti JG, 2000, AM J RESP CRIT CARE, V161, pA507